SERCA 2a Gene Therapy, Game-Changer for Heart Failure

Submit Manuscript | http://medcraveonline.com transients recorded with the Ca2+ probe aequorin during isometric contraction of myocardium in patients with end-stage failure were markedly prolonged, with a peak and then a secondary peak in the [Ca2+]i transient trace, which was associated with a marked prolongation of the time course of the Ca2+ decline and of tension decline [2]. Because SERCA is responsible for 60% to 90% of the [Ca2+]i decline in mammalian ventricular myocytes, these results were consistent with impaired function of the SR Ca2+ transport system.